{ "nodes": [ [ "Botulinum Toxins, Type A", "GENE" ], [ "calcitonin gene-related peptide", "GENE" ], [ "HTR1F", "GENE" ], [ "Receptors, Calcitonin Gene-Related Peptide", "GENE" ], [ "Episodic migraine", "DISEASE" ], [ "CGRP", "GENE" ], [ "rimegepant", "DRUG" ], [ "Nausea", "DISEASE" ], [ "Acute migraine", "DISEASE" ], [ "Headache", "DISEASE" ], [ "Migraine Disorders", "DISEASE" ] ], "edges": [ [ [ "rimegepant", "CGRP" ], 19.810872, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The journal of headache and pain, 4. https://doi.org/10.1186/s10194-024-01935-8 PMID: 39762740", "39762740" ], [ "Samaira Younis, Nina V Latysheva, Alexey B Danilov, Messoud Ashina (2024). CGRP receptor antagonists (gepants). Handbook of clinical neurology, 51-66. https://doi.org/10.1016/B978-0-12-823357-3.00033-1 PMID: 38307667", "38307667" ], [ "Tessa de Vries, Eloísa Rubio-Beltrán, Antoon van den Bogaerdt, Ruben Dammers, A H Jan Danser, Josefin Snellman, Jeanine Bussiere, Antoinette MaassenVanDenBrink (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British journal of pharmacology, 1720-1733. https://doi.org/10.1111/bph.16322 PMID: 38320397", "38320397" ], [ "Yiya Zhang, Tao Li, Han Zhao, Xin Xiao, Ximin Hu, Ben Wang, Yingxue Huang, Zhinan Yin, Yun Zhong, Yangfan Li, Ji Li (2024). High-sensitive sensory neurons exacerbate rosacea-like dermatitis in mice by activating γδ T cells directly. Nature communications, 7265. https://doi.org/10.1038/s41467-024-50970-1 PMID: 39179539", "39179539" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Lanfranco Pellesi, Paolo Martelletti (2024). Situational prevention in migraine: are we doing the right thing? The journal of headache and pain, 137. https://doi.org/10.1186/s10194-024-01841-z PMID: 39174943", "39174943" ], [ "Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry, Meghan Lovegren, Gilbert L'Italien, Richard B Lipton (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia : an international journal of headache, 3331024241232944. https://doi.org/10.1177/03331024241232944 PMID: 38659334", "38659334" ], [ "Ryan Thaliffdeen, Anthony Yu, Karen Rascati (2024). Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model. Clinical drug investigation, 209-217. https://doi.org/10.1007/s40261-024-01345-3 PMID: 38381352", "38381352" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ] ] ], [ [ "rimegepant", "Receptors, Calcitonin Gene-Related Peptide" ], 8.967867, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Lanxin Jiang, Ying Zhou, Shijie Tang, Dan Yang, Yixin Zhang, Jiuge Zhang, Fan Yang, Tong Zhou, Xiaoqiang Xia, Qianming Chen, Lu Jiang, Yuchen Jiang, Xiaodong Feng (2024). Nociceptive adenosine A2A receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma. International journal of oral science, 46. https://doi.org/10.1038/s41368-024-00308-w PMID: 38886342", "38886342" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Samaira Younis, Nina V Latysheva, Alexey B Danilov, Messoud Ashina (2024). CGRP receptor antagonists (gepants). Handbook of clinical neurology, 51-66. https://doi.org/10.1016/B978-0-12-823357-3.00033-1 PMID: 38307667", "38307667" ], [ "Tessa de Vries, Eloísa Rubio-Beltrán, Antoon van den Bogaerdt, Ruben Dammers, A H Jan Danser, Josefin Snellman, Jeanine Bussiere, Antoinette MaassenVanDenBrink (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British journal of pharmacology, 1720-1733. https://doi.org/10.1111/bph.16322 PMID: 38320397", "38320397" ], [ "Yiya Zhang, Tao Li, Han Zhao, Xin Xiao, Ximin Hu, Ben Wang, Yingxue Huang, Zhinan Yin, Yun Zhong, Yangfan Li, Ji Li (2024). High-sensitive sensory neurons exacerbate rosacea-like dermatitis in mice by activating γδ T cells directly. Nature communications, 7265. https://doi.org/10.1038/s41467-024-50970-1 PMID: 39179539", "39179539" ], [ "Richard B Lipton, Alexandra Thiry, Beth A Morris, Robert Croop (2024). Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of pain research, 2431-2441. https://doi.org/10.2147/JPR.S453806 PMID: 39070853", "39070853" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Edoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich (2024). CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Handbook of clinical neurology, 107-124. https://doi.org/10.1016/B978-0-12-823357-3.00024-0 PMID: 38307640", "38307640" ], [ "(2024). Erratum: Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]. Journal of pain research, 4085-4086. https://doi.org/10.2147/JPR.S499096 PMID: 39650209", "39650209" ] ] ], [ [ "rimegepant", "Episodic migraine" ], 15.492134, [ [ "Ryan Thaliffdeen, Anthony Yu, Karen Rascati (2024). Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model. Clinical drug investigation, 209-217. https://doi.org/10.1007/s40261-024-01345-3 PMID: 38381352", "38381352" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Gilwan Kim, Margaret Hoyt, Armen Zakharyan, Jennifer Durica, Alexandra Wallem, Lars Viktrup (2024). Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis. Advances in therapy. https://doi.org/10.1007/s12325-024-03072-9 PMID: 39680312", "39680312" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Jessica Ailani, Pranav Gandhi, Anjana Lalla, Rashmi Halker Singh, Peter McAllister, Jonathan H Smith, Brett Dabruzzo, Natty Chalermpalanupap, Kari Kelton, Stephanie J Nahas (2024). Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine. Headache, 1253-1263. https://doi.org/10.1111/head.14824 PMID: 39248007", "39248007" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Lars Edvinsson (2024). Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. Expert review of neurotherapeutics, 1141-1155. https://doi.org/10.1080/14737175.2024.2434079 PMID: 39620902", "39620902" ], [ "Rajinder Bhardwaj, Beth Morris, Kyle T Matschke, Richard Bertz, Robert Croop, Jing Liu (2024). Characterization of rimegepant drug-drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam. Headache. https://doi.org/10.1111/head.14836 PMID: 39364583", "39364583" ], [ "Todd J Schwedt, Tina M Myers Oakes, James M Martinez, Bert B Vargas, Hitendra Pandey, Eric M Pearlman, Diane R Richardson, Oralee J Varnado, Michael Cobas Meyer, Peter J Goadsby (2023). Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial. Neurology and therapy. https://doi.org/10.1007/s40120-023-00562-w PMID: 37948006", "37948006" ], [ "Hannah A Blair (2023). Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine. CNS drugs, 255-265. https://doi.org/10.1007/s40263-023-00988-8 PMID: 36739335", "36739335" ] ] ], [ [ "rimegepant", "Acute migraine" ], 24.896476, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The journal of headache and pain, 4. https://doi.org/10.1186/s10194-024-01935-8 PMID: 39762740", "39762740" ], [ "Emmanouil V Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S Vlachos, Georgios G Vasiliadis, Andreas A Argyriou (2024). Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study. Brain sciences. https://doi.org/10.3390/brainsci14121169 PMID: 39766367", "39766367" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Zhao Yang, Xiaodan Wang, Mengyue Niu, Qiao Wei, Huizhu Zhong, Xiaoyan Li, Weihong Yuan, Wenli Xu, Shuo Zhu, Shengyuan Yu, Jun Liu, Jianzhou Yan, Wenyan Kang, Peijian Huang (2024). First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients. The journal of headache and pain, 160. https://doi.org/10.1186/s10194-024-01873-5 PMID: 39333875", "39333875" ], [ "Zifan Zhou, Robert Urman, Karminder Gill, Andrew S Park, Fiston Vuvu, Leah B Patel, Jingsong Lu, Rolin L Wade, Lindsay Frerichs, Mark E Bensink (2023). Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. The journal of headache and pain, 153. https://doi.org/10.1186/s10194-023-01678-y PMID: 37946113", "37946113" ], [ "Irene de Boer, Iris Elsa Verhagen, Marcio Nattan Portes Souza, Messoud Ashina (2023). Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia : an international journal of headache, 3331024221143773. https://doi.org/10.1177/03331024221143773 PMID: 36739516", "36739516" ], [ "Oralee J Varnado, Tania Gulati, Anthony Wheeler, Margaret Hoyt (2023). Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States. Patient preference and adherence, 3449-3459. https://doi.org/10.2147/PPA.S435782 PMID: 38143945", "38143945" ], [ "Rajinder Bhardwaj, Joseph C Stringfellow, Beth Morris, Robert S Croop, Richard J Bertz (2023). Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants. Headache, 652-662. https://doi.org/10.1111/head.14512 PMID: 37140071", "37140071" ], [ "Gareth Iacobucci (2023). NICE recommends rimegepant for treating acute migraine in adults. BMJ (Clinical research ed.), 2104. https://doi.org/10.1136/bmj.p2104 PMID: 37709356", "37709356" ] ] ], [ [ "rimegepant", "Botulinum Toxins, Type A" ], 4.2442014, [ [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Hema Mistry, Seyran Naghdi, Anna Brown, Sophie Rees, Jason Madan, Amy Grove, Saval Khanal, Callum Duncan, Manjit Matharu, Andrew Cooklin, Aiva Aksentyte, Natasha Davies, Martin Underwood (2024). Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health technology assessment (Winchester, England), 1-329. https://doi.org/10.3310/AYWA5297 PMID: 39365169", "39365169" ], [ "(2023). Drugs for migraine. The Medical letter on drugs and therapeutics, 89-96. https://doi.org/10.58347/tml.2023.1678a PMID: 37266987", "37266987" ], [ "(2023). Comparison table: Some drugs for migraine prevention in adults. The Medical letter on drugs and therapeutics, e100-e102. https://doi.org/10.58347/tml.2023.1678c PMID: 37266989", "37266989" ], [ "(2021). Atogepant (Qulipta) for migraine prevention. The Medical letter on drugs and therapeutics, 169-171. PMID: 35085204", "35085204" ], [ "Matthew S Robbins (2021). Diagnosis and Management of Headache: A Review. JAMA, 1874-1885. https://doi.org/10.1001/jama.2021.1640 PMID: 33974014", "33974014" ], [ "(2020). Drugs for Migraine. The Medical letter on drugs and therapeutics, 153-160. PMID: 33434187", "33434187" ], [ "Luana Lionetto, Andrea Negro, Stefano Palmisani, Giovanna Gentile, Maria Rosaria Del Fiore, Marco Mercieri, Maurizio Simmaco, Thomas Smith, Adnan Al-Kaisy, Roberto Arcioni, Paolo Martelletti (2012). Emerging treatment for chronic migraine and refractory chronic migraine. Expert opinion on emerging drugs, 393-406. https://doi.org/10.1517/14728214.2012.709846 PMID: 22862686", "22862686" ] ] ], [ [ "rimegepant", "Headache" ], 28.148692, [ [ "Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The journal of headache and pain, 4. https://doi.org/10.1186/s10194-024-01935-8 PMID: 39762740", "39762740" ], [ "Emmanouil V Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S Vlachos, Georgios G Vasiliadis, Andreas A Argyriou (2024). Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study. Brain sciences. https://doi.org/10.3390/brainsci14121169 PMID: 39766367", "39766367" ], [ "X Moisset, G Demarquay, S de Gaalon, C Roos, A Donnet, P Giraud, E Guégan-Massardier, C Lucas, J Mawet, D Valade, V Corand, C Gollion, N Moreau, L Grangeon, M Lantéri-Minet, A Ducros (2024). Migraine treatment: Position paper of the French Headache Society. Revue neurologique, 1087-1099. https://doi.org/10.1016/j.neurol.2024.09.008 PMID: 39406556", "39406556" ], [ "Anjaneya Shankar Madhav Bandatmakur, Pooja Dave, Melissa Kerr, Colin Brunick, Sijin Wen, Nicholas Hansen (2024). Effectiveness and Tolerability of Anti-Calcitonin Gene-Related Peptide Therapy for Migraine and Other Chronic Headaches in Adolescents and Young Adults: A Retrospective Study in the USA. Brain sciences. https://doi.org/10.3390/brainsci14090879 PMID: 39335375", "39335375" ], [ "Samaira Younis, Nina V Latysheva, Alexey B Danilov, Messoud Ashina (2024). CGRP receptor antagonists (gepants). Handbook of clinical neurology, 51-66. https://doi.org/10.1016/B978-0-12-823357-3.00033-1 PMID: 38307667", "38307667" ], [ "Andrew C Charles, Kathleen B Digre, Peter J Goadsby, Matthew S Robbins, Andrew Hershey, (2024). Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache, 333-341. https://doi.org/10.1111/head.14692 PMID: 38466028", "38466028" ], [ "Cristina Tassorelli, Kateryna Onishchenko, Rashmi B Halker Singh, Molly Duan, Laure Dupont-Benjamin, Matthew Hemstock, Corey Voller, Peter McAllister, Stephanie J Nahas, Pranav Gandhi, Jessica Ailani (2024). Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia : an international journal of headache, 3331024241235156. https://doi.org/10.1177/03331024241235156 PMID: 38410850", "38410850" ], [ "William David Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti (2024). Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert review of neurotherapeutics, 1107-1117. https://doi.org/10.1080/14737175.2024.2401558 PMID: 39264231", "39264231" ], [ "Jessica Ailani, Motomori Lewis, Feng Dai, Aaron Jenkins, Jessica Cirillo, Karin Hygge Blakeman, Lucy Abraham, Joshua Brown (2024). Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study. Current medical research and opinion, 1913-1920. https://doi.org/10.1080/03007995.2024.2410930 PMID: 39340768", "39340768" ], [ "Shuo Tian, Yuping Yang, Shenglan Tan, Jiani Luo, Chuanyu Yang, Qiao Liu, Yujin Guo (2024). Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China. Frontiers in neurology, 1411576. https://doi.org/10.3389/fneur.2024.1411576 PMID: 39246609", "39246609" ] ] ], [ [ "rimegepant", "Migraine Disorders" ], 148.27362, [ [ "Abimael González-Hernández, Carlos M Villalón (2025). The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review. Expert opinion on drug metabolism & toxicology, 41-52. https://doi.org/10.1080/17425255.2024.2409253 PMID: 39319681", "39319681" ], [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "A Mínguez-Olaondo, A López-Bravo, S Quintas, C Nieves-Castellanos, A Layos-Romero, R Belvís, P Irimia, S Díaz-Insa (2024). [New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants]. Revista de neurologia, 47-57. https://doi.org/10.33588/rn.7802.2023176 PMID: 38223948", "38223948" ], [ "Cristina Tassorelli, Kateryna Onishchenko, Rashmi B Halker Singh, Molly Duan, Laure Dupont-Benjamin, Matthew Hemstock, Corey Voller, Peter McAllister, Stephanie J Nahas, Pranav Gandhi, Jessica Ailani (2024). Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis. Cephalalgia : an international journal of headache, 3331024241235156. https://doi.org/10.1177/03331024241235156 PMID: 38410850", "38410850" ], [ "Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, Duangnapa Roongpiboonsopit, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong (2024). Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis. The journal of headache and pain, 194. https://doi.org/10.1186/s10194-024-01904-1 PMID: 39516789", "39516789" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Richard B Lipton (2024). Preventive Treatment of Migraine. Continuum (Minneapolis, Minn.), 364-378. https://doi.org/10.1212/CON.0000000000001418 PMID: 38568488", "38568488" ], [ "Hema Mistry, Seyran Naghdi, Anna Brown, Sophie Rees, Jason Madan, Amy Grove, Saval Khanal, Callum Duncan, Manjit Matharu, Andrew Cooklin, Aiva Aksentyte, Natasha Davies, Martin Underwood (2024). Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling. Health technology assessment (Winchester, England), 1-329. https://doi.org/10.3310/AYWA5297 PMID: 39365169", "39365169" ], [ "Terence Fullerton, Glenn Pixton (2024). Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics. Journal of pain research, 1751-1760. https://doi.org/10.2147/JPR.S456006 PMID: 38764606", "38764606" ], [ "Deirdre M Boucherie, Ruben Dammers, Arnaud Vincent, A H Jan Danser, Antoinette MaassenVanDenBrink (2024). Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics. The journal of headache and pain, 141. https://doi.org/10.1186/s10194-024-01846-8 PMID: 39198753", "39198753" ] ] ], [ [ "rimegepant", "HTR1F" ], 3.186754, [ [ "Oyindamola I Ogunlaja, Peter J Goadsby (2022). Headache: Treatment update. eNeurologicalSci, 100420. https://doi.org/10.1016/j.ensci.2022.100420 PMID: 36636337", "36636337" ], [ "Kayla Rena Joyner, Kelsey Woods Morgan (2021). Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. The Annals of pharmacotherapy, 745-759. https://doi.org/10.1177/1060028020963574 PMID: 32993366", "32993366" ], [ "Linda Harris, Gilbert L'Italien, Thomas O'Connell, Zacharia Hasan, Susan Hutchinson, Sylvia Lucas (2021). A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States. Advances in therapy, 5087-5097. https://doi.org/10.1007/s12325-021-01781-z PMID: 34057676", "34057676" ], [ "Chun-Pai Yang, Kuo-Ting Huang, Ching-Mao Chang, Cheng-Chia Yang, Shuu-Jiun Wang (2021). Acute Treatment of Migraine: What has Changed in Pharmacotherapies? Neurology India, S25-S42. https://doi.org/10.4103/0028-3886.315995 PMID: 34003146", "34003146" ], [ "Alok Singh, Dhyuti Gupta, Abhishek Singh (2021). Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety. Neurology India, S43-S50. https://doi.org/10.4103/0028-3886.315991 PMID: 34003147", "34003147" ], [ "Juliana K Beauchene, Terri L Levien (2021). Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 244-253. https://doi.org/10.1177/87551225211024630 PMID: 34752575", "34752575" ], [ "Andrea Negro, Paolo Martelletti (2021). Novel synthetic treatment options for migraine. Expert opinion on pharmacotherapy, 907-922. https://doi.org/10.1080/14656566.2020.1862793 PMID: 33369482", "33369482" ], [ "Matthew S Robbins (2021). Diagnosis and Management of Headache: A Review. JAMA, 1874-1885. https://doi.org/10.1001/jama.2021.1640 PMID: 33974014", "33974014" ], [ "Flavia Lo Castro, Simona Guerzoni, Lanfranco Pellesi (2021). Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug, healthcare and patient safety, 233-240. https://doi.org/10.2147/DHPS.S304373 PMID: 34849034", "34849034" ], [ "Jessica Ailani, Rebecca C Burch, Matthew S Robbins, (2021). The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache, 1021-1039. https://doi.org/10.1111/head.14153 PMID: 34160823", "34160823" ] ] ], [ [ "rimegepant", "Nausea" ], 16.583163000000003, [ [ "Emmanouil V Dermitzakis, Dimitrios Rikos, Michail Vikelis, Georgia Xiromerisiou, Styliani Zisopoulou, Dimitrios Rallis, Panagiotis Soldatos, George S Vlachos, Georgios G Vasiliadis, Andreas A Argyriou (2024). Real-World Open-Label Experience with Rimegepant for the Acute Treatment of Migraine Attacks: A Multicenter Pilot Study. Brain sciences. https://doi.org/10.3390/brainsci14121169 PMID: 39766367", "39766367" ], [ "Pooja Singh, Rakesh Kumar Ponnada, Ruchika Sharma, Bommaraju Sumadhura, Anoop Kumar, Ashok Kumar Datusalia (2024). Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis. CNS & neurological disorders drug targets, 1474-1487. https://doi.org/10.2174/0118715273304677240529062909 PMID: 38847252", "38847252" ], [ "Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li (2024). Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases. Frontiers in pharmacology, 1431562. https://doi.org/10.3389/fphar.2024.1431562 PMID: 39144633", "39144633" ], [ "Karissa Johnston, Lauren C Powell, Evan Popoff, Gil J L'Italien, Robert Pawinski, Aideen Ahern, Sam Large, Thang Tran, Aaron Jenkins (2024). Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK. Journal of medical economics, 627-643. https://doi.org/10.1080/13696998.2024.2340932 PMID: 38590236", "38590236" ], [ "Richard B Lipton, Alexandra Thiry, Beth A Morris, Robert Croop (2024). Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of pain research, 2431-2441. https://doi.org/10.2147/JPR.S453806 PMID: 39070853", "39070853" ], [ "Hong Pan, Shasha Lin (2024). A real-world adverse events study of rimegepant from the FAERS database. Expert opinion on drug safety, 1-6. https://doi.org/10.1080/14740338.2024.2418319 PMID: 39412590", "39412590" ], [ "Francesca Puledda, Samaira Younis, Eva-Maria Huessler, Faraidoon Haghdoost, Marco Lisicki, Peter J Goadsby, Cristina Tassorelli (2023). Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia : an international journal of headache, 3331024231151419. https://doi.org/10.1177/03331024231151419 PMID: 36786357", "36786357" ], [ "Shengyuan Yu, Byung-Kun Kim, Aihong Guo, Man-Ho Kim, Mingjie Zhang, Zhen Wang, Jianguang Liu, Heui-Soo Moon, Ge Tan, Qian Yang, Donnie McGrath, Michael Hanna, David A Stock, Yanfei Gao, Robert Croop, Zhihong Lu (2023). Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet. Neurology, 476-484. https://doi.org/10.1016/S1474-4422(23)00126-6 PMID: 37210098", "37210098" ], [ "Guojun Dong, Naoko Adachi Kjærgaard, Saeed Shakibfar, Maurizio Sessa (2023). Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. Expert opinion on drug safety, 59-70. https://doi.org/10.1080/14740338.2023.2177270 PMID: 36737057", "36737057" ], [ "Claudia Altamura, Nicoletta Brunelli, Marilena Marcosano, Luisa Fofi, Fabrizio Vernieri (2022). Gepants - a long way to cure: a narrative review. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 5697-5708. https://doi.org/10.1007/s10072-022-06184-8 PMID: 35650458", "35650458" ] ] ], [ [ "rimegepant", "calcitonin gene-related peptide" ], 13.571744, [ [ "Patrick Eugeni, Megan E Rooney, Nicolas P Saikali, Zhongzheng Niu, Maurice T Driessen, Lynda J Krasenbaum, Karen Carr, Michael J Seminerio, Jennifer W McVige (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in therapy. https://doi.org/10.1007/s12325-024-03063-w PMID: 39775579", "39775579" ], [ "Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, (2025). Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). The journal of headache and pain, 4. https://doi.org/10.1186/s10194-024-01935-8 PMID: 39762740", "39762740" ], [ "Samaira Younis, Nina V Latysheva, Alexey B Danilov, Messoud Ashina (2024). CGRP receptor antagonists (gepants). Handbook of clinical neurology, 51-66. https://doi.org/10.1016/B978-0-12-823357-3.00033-1 PMID: 38307667", "38307667" ], [ "David Kudrow, Susan Hutchinson, Glenn C Pixton, Terence Fullerton (2024). Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain and therapy. https://doi.org/10.1007/s40122-024-00675-6 PMID: 39520634", "39520634" ], [ "Pooja Singh, Rakesh Kumar Ponnada, Ruchika Sharma, Bommaraju Sumadhura, Anoop Kumar, Ashok Kumar Datusalia (2024). Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis. CNS & neurological disorders drug targets, 1474-1487. https://doi.org/10.2174/0118715273304677240529062909 PMID: 38847252", "38847252" ], [ "Tessa de Vries, Eloísa Rubio-Beltrán, Antoon van den Bogaerdt, Ruben Dammers, A H Jan Danser, Josefin Snellman, Jeanine Bussiere, Antoinette MaassenVanDenBrink (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British journal of pharmacology, 1720-1733. https://doi.org/10.1111/bph.16322 PMID: 38320397", "38320397" ], [ "Yiya Zhang, Tao Li, Han Zhao, Xin Xiao, Ximin Hu, Ben Wang, Yingxue Huang, Zhinan Yin, Yun Zhong, Yangfan Li, Ji Li (2024). High-sensitive sensory neurons exacerbate rosacea-like dermatitis in mice by activating γδ T cells directly. Nature communications, 7265. https://doi.org/10.1038/s41467-024-50970-1 PMID: 39179539", "39179539" ], [ "Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick (2024). Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex. Cephalalgia : an international journal of headache, 3331024241238153. https://doi.org/10.1177/03331024241238153 PMID: 38477313", "38477313" ], [ "Lanfranco Pellesi, Paolo Martelletti (2024). Situational prevention in migraine: are we doing the right thing? The journal of headache and pain, 137. https://doi.org/10.1186/s10194-024-01841-z PMID: 39174943", "39174943" ], [ "Robert Croop, Gary Berman, David Kudrow, Kathleen Mullin, Alexandra Thiry, Meghan Lovegren, Gilbert L'Italien, Richard B Lipton (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia : an international journal of headache, 3331024241232944. https://doi.org/10.1177/03331024241232944 PMID: 38659334", "38659334" ] ] ] ] }